AKBA
Akebia Therapeutics Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$1.28
+0.06 ▲ +4.92%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$1.28
+0.00 +0.02%
아케비아 테라퓨틱스(AKBA) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
시가총액
$343M
스몰캡
P/E
-
배당수익률
없음
52주 위치
15%
저점 +56% · 고점 -67%
애널리스트
적극 매수
C+
Fundamental health
vs. Drug Manufacturers - Specialty & Generic 소형주
수익성 Top 35%
성장 Top 61%
밸류에이션 Top 37%
재무 안정 Top 71%
| Index | RUT | P/E | - | EPS (ttm) | -0.08 | Insider Own | 2.8% | Shs Outstand | 267.9M | Perf Week | - |
| Market Cap | 0.34B | Forward P/E | - | EPS next Y | -83.33% | Insider Trans | -7.79% | Shs Float | 260.8M | Perf Month | 23.08% |
| Enterprise Value | 0.40B | PEG | - | EPS next Q | -0.04 | Inst Own | 39.63% | Short Float | 7.32% | Perf Quarter | -10.49% |
| Income | -0.02B | P/S | 1.48 | EPS this Y | -620% | Inst Trans | -6.74% | Short Ratio | 3.81 | Perf Half Y | -5.88% |
| Sales | 0.23B | P/B | 12.53 | EPS next 5Y | - | ROA | -6.1% | Short Interest | 19.08M | Perf YTD | -20.5% |
| Book/sh | 0.1 | P/C | 2.09 | EPS past 3/5Y | 65.7% 62.4% | ROE | -78.96% | 52W High | -66.75% ($3.85) | Perf Year | -64.04% |
| Cash/sh | 0.61 | P/FCF | 5.72 | Sales past 3/5Y | -6.88% -4.37% | ROIC | -11.06% | 52W Low | 55.59% ($0.82) | Perf 3Y | -15.79% |
| Dividend Est. | - | EV/EBITDA | 60.42 | EPS Y/Y TTM | 64.06% | Gross Margin | 80.46% | Volatility(W/M) | 5.4% 6.49% | Perf 5Y | -49.41% |
| Dividend TTM | - | EV/Sales | 1.71 | Sales Y/Y TTM | 25.69% | Oper. Margin | 2.28% | ATR (14) | 0.07 | Perf 10Y | -86.06% |
| Dividend Ex-Date | - | Quick Ratio | 1.33 | EPS Q/Q | -233.99% | Profit Margin | -8.83% | RSI (14) | 53.58 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.4 | Sales Q/Q | -6.61% | SMA20 | -1.8% ($1.3) | Beta | 0.26 | Target Price | $4.2 |
| Payout | - | Debt/Eq | 7.96 | Earnings | 2026/5/7 | SMA50 | 13.92% ($1.12) | Rel Volume | 0.37 | Prev Close | $1.22 |
| Employees | 194 | LT Debt/Eq | 5.77 | EPS/Sales Surpr. | -7.14% 3.63% | SMA200 | -15.04% ($1.51) | Avg Volume(3M) | 5.01M | Price | $1.28 |
| IPO | 2014/3/20 | Option/Short | Yes/Yes | Trades | 6956 | Volume | 1,857,211 | Change | 4.92% |
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $54M (YoY -7%) · 순이익 $-9M (YoY -248%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red
Akebia Therapeutics Inc (AKBA) Investment Analysis
What kind of company is Akebia Therapeutics Inc?
아케비아 테라퓨틱스(AKBA) 방어주
Healthcare · Drug Manufacturers - Specialty & Generic
Small-Cap — Low Volume, High Volatility
🩺 This is a US biopharmaceutical company specializing in kidney diseases, primarily focused on anemia treatments for patients with chronic kidney disease. The company has commercialized Vafseo (vadadustat), an oral anemia treatment for dialysis patients, and Auryxia (ferric citrate), a phosphate binder. It is a specialty and generic pharmaceutical company that is expanding its pipeline for rare kidney diseases.
Learn more about Akebia Therapeutics Inc →Market Cap
$0.3B
Approx. KRW 0.5 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank3571
Employees194people
IPO2014/03/20
Current Price$1.28 ≈ 1,754원
Key Events
⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 7일 (목) · 장 시작 전 EPS -7.1% 매출 +3.6%
🔔 Earnings release 2026년 2월 26일 (목) · 장 시작 전 EPS -38.9% 매출 +25.0%
Is it profitable?
Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
2.3%
✓ 평균
Net Margin
Share of revenue left after taxes and interest are paid
-8.8%
✓ 적자
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
80.5%
✓ 우수
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-79.0%
✓ 적자
ROA
Annual earnings relative to total company assets
-6.1%
✓ 적자
ROIC
Return generated per dollar invested in the business
-11.1%
✓ 적자
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
7.96
✓ Danger level
Current Ratio
Liquid assets available to cover liabilities due within a year
1.40
✓ 평균
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.33
✓ 양호
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).
What's the outlook?
Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$4.20
현재가 대비 +228.1%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
-83.3%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.
Did earnings meet expectations?
Average Earnings Performance
Mixed beats and misses
1
예상 상회
0
예상 부합
1
예상 하회
50%
상회 비율
-16.7%
평균 서프라이즈
2026.05.07
하회
실적 $-0.03 · 예상 $-0.02 -50.0%
2026.02.26
상회
실적 $-0.05 · 예상 $-0.06 +16.7%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.
Is it growing?
Growth Expected to Slow
Historical growth is expected to lose momentum
Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
-620.0%
매우 부진
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
-83.3%
매우 부진
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+65.7%
우수
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+62.4%
우수
Past 5-Year Revenue
How much revenue grew over the past 5 years
-4.4%
부진
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
-6.6%
부진
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →
Has the stock risen over the long term?
Long-term weakness — -118%p below the market
AKBA -49.4% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-117.8%p
Significantly behind the market
vs Health Care (XLV)
-73.9%p
Significantly behind the sector average
1-year basis
vs S&P 500
-80.1%p
Significantly behind the market
vs Health Care (XLV)
-83.8%p
Significantly behind the sector average
Rank among peers
5-year return Upper-Mid (48%) Based on 25 peers
1-year return Bottom 11% Based on 28 peers
Current position within 52-week range
Low (-55.6%p) High (-66.8%p)
Current price is 55.6% above the 52-week low and 66.8% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-44.2%
Annualized volatility
74.3%
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current diagnosis · 2026-07-27
Downtrend zone
Current price $1.28 below the midline ($1.30). Normal downward flow. Above the Ichimoku cloud (bullish).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
Current diagnosis · 2026-07-27
Neutral zone — weak trend
MACD 0.035 · Signal 0.056 · Hist -0.021. Weak directional bias.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
Current diagnosis · 2026-07-27
Bullish zone
RSI 53.7 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 33.3.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
In line with the industry average
Cheap on Vs. Sales, Pricey on Vs. Assets, In line with peers on Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
Vs. Assets Pricey
Vs. Sales Cheap
Vs. Cash Flow Mid-range
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
12.53x
✓ Pricey
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
1.48x
✓ Cheap
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
60.42x
✓ Very pricey
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
5.72x
✓ Cheap
Analyst target price (reference)
$4.20 vs. current price +228.1%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic 소형주
Who owns it?
Ownership flow shows some pressure
Insider modest net selling -7.8% · Institutional net selling -6.7% · Short interest moderate 7.3% · Short interest fell -4.2%p over the last 90 days
📈 Recent trading flow (6 months)
🧑💼 Insiders (executives & directors)
-7.8%
Insiders net selling
🏦 Institutions (funds & investors)
-6.7%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 39.6%
Moderate institutional participation
🧑💼 Insiders 2.8%
Typical level
👤 Retail investors (estimated) 57.6%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
7.3%
Moderate
Past 90 days 📉 -4.2%p decrease
Short interest days to cover
3.8 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 267.9M주
Float (tradable shares) 260.8M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.
ETFs holding AKBA
ETFs with the highest weightings · 10 total shown
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.
How much does it pay in dividends?
This company does not pay a dividend
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| AKBA This Stock | $343.4M | - | 12.5 ▼ | -78.96% ▼ | - | +4.9% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
FAQ
What kind of company is 아케비아 테라퓨틱스(AKBA)?
아케비아 테라퓨틱스(AKBA) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of AKBA?
The market cap of AKBA is approximately $343M, ranking 3,571 within its sector.
What is the 52-week high and low for AKBA?
AKBA has recorded a 52-week high of $3.85 and a low of $0.82.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.